Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325442 ·Status: COMPLETED ·Phase: PHASE3

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

NCT01477333 ·Status: COMPLETED ·Phase: PHASE2

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916 ·Status: WITHDRAWN ·Phase: PHASE3

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

NCT03794583 ·Status: TERMINATED ·Phase: PHASE3

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

NCT01557647 ·Status: WITHDRAWN ·Phase: PHASE3

Remodulin® to Oral Treprostinil Transition

NCT01588405 ·Status: COMPLETED ·Phase: PHASE2

Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)

NCT02074449 ·Status: COMPLETED

Inhaled Treprostinil for PAH: Open-label Extension

NCT01557660 ·Status: WITHDRAWN ·Phase: PHASE3

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

NCT00147199 ·Status: COMPLETED ·Phase: PHASE3

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325403 ·Status: COMPLETED ·Phase: PHASE3

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580 ·Status: TERMINATED ·Phase: PHASE3

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

NCT03554291 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

NCT00091715 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

NCT02279160 ·Status: COMPLETED ·Phase: PHASE2

A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)

NCT05553015 ·Status: RECRUITING

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

NCT00705133 ·Status: COMPLETED ·Phase: PHASE2

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT03015402 ·Status: COMPLETED ·Phase: PHASE2

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

NCT00323024 ·Status: WITHDRAWN ·Phase: PHASE2

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension

NCT01523548 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]

NCT01696240 ·Status: UNKNOWN ·Phase: PHASE3

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

NCT01934582 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension

NCT07177703 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

NCT02893995 ·Status: WITHDRAWN ·Phase: PHASE4

Upfront Combination Pulmonary Arterial Hypertension Therapy

NCT03809156 ·Status: UNKNOWN ·Phase: PHASE4

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739 ·Status: COMPLETED ·Phase: PHASE1